403 related articles for article (PubMed ID: 15480846)
1. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
2. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Youdim MB; Bakhle YS
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
[TBL] [Abstract][Full Text] [Related]
3. BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease.
Ledreux A; Boger HA; Hinson VK; Cantwell K; Granholm AC
Brain Res; 2016 Jan; 1631():34-45. PubMed ID: 26607251
[TBL] [Abstract][Full Text] [Related]
4. Dual-target anti-Alzheimer's disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity.
Mi Z; Gan B; Yu S; Guo J; Zhang C; Jiang X; Zhou T; Su J; Bai R; Xie Y
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1489-1497. PubMed ID: 31416364
[TBL] [Abstract][Full Text] [Related]
5. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
[TBL] [Abstract][Full Text] [Related]
6. Loss of DJ-1 function contributes to Parkinson's disease pathogenesis in mice via RACK1-mediated PKC activation and MAO-B upregulation.
Liu LL; Han Y; Zhang ZJ; Wang YQ; Hu YW; Kaznacheyeva E; Ding JQ; Guo DK; Wang GH; Li B; Ren HG
Acta Pharmacol Sin; 2023 Oct; 44(10):1948-1961. PubMed ID: 37225849
[TBL] [Abstract][Full Text] [Related]
7.
Boulaamane Y; Ibrahim MAA; Britel MR; Maurady A
J Integr Bioinform; 2022 Dec; 19(4):. PubMed ID: 36112816
[TBL] [Abstract][Full Text] [Related]
8. Predicting monoamine oxidase inhibitory activity through ligand-based models.
Vilar S; Ferino G; Quezada E; Santana L; Friedman C
Curr Top Med Chem; 2012; 12(20):2258-74. PubMed ID: 23231398
[TBL] [Abstract][Full Text] [Related]
9. KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease.
Nam MH; Park JH; Song HJ; Choi JW; Kim S; Jang BK; Yoon HH; Heo JY; Lee H; An H; Kim HJ; Park SJ; Cho DW; Yang YS; Han SC; Kim S; Oh SJ; Jeon SR; Park KD; Lee CJ
Neurotherapeutics; 2021 Jul; 18(3):1729-1747. PubMed ID: 34611843
[TBL] [Abstract][Full Text] [Related]
10. Identification and Characterization of Neuroprotective Properties of Thaumatin-like Protein 1a from
D'Errico A; Nasso R; Di Maro A; Landi N; Chambery A; Russo R; D'Angelo S; Masullo M; Arcone R
Nutrients; 2024 Jan; 16(2):. PubMed ID: 38276545
[TBL] [Abstract][Full Text] [Related]
11. Effect of Hydroxytyrosol Derivatives of Donepezil on the Activity of Enzymes Involved in Neurodegenerative Diseases and Oxidative Damage.
D'Errico A; Nasso R; Rullo R; Maiuolo J; Costanzo P; Bonacci S; Oliverio M; De Vendittis E; Masullo M; Arcone R
Molecules; 2024 Jan; 29(2):. PubMed ID: 38276626
[TBL] [Abstract][Full Text] [Related]
12. DFT, ADME studies and evaluation of the binding with HSA and MAO-B inhibitory potential of protoberberine alkaloids from Guatteria friesiana: theoretical insights of promising candidates for the treatment of Parkinson's disease.
Tananta VL; Costa EV; Mary YS; Mary YS; S Al-Otaibi J; Costa RA
J Mol Model; 2023 Nov; 29(11):353. PubMed ID: 37907772
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
Sturm S; Forsberg A; Nave S; Stenkrona P; Seneca N; Varrone A; Comley RA; Fazio P; Jamois C; Nakao R; Ejduk Z; Al-Tawil N; Akenine U; Halldin C; Andreasen N; Ricci B
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):382-391. PubMed ID: 27633250
[TBL] [Abstract][Full Text] [Related]
14. The monoamine oxidase inhibitory activity of essential oils obtained from Eryngium species and their chemical composition.
Klein-Júnior LC; dos Santos Passos C; Tasso de Souza TJ; Gobbi de Bitencourt F; Salton J; de Loreto Bordignon SA; Henriques AT
Pharm Biol; 2016; 54(6):1071-6. PubMed ID: 26810928
[TBL] [Abstract][Full Text] [Related]
15. MAO-inhibitors in Parkinson's Disease.
Riederer P; Laux G
Exp Neurobiol; 2011 Mar; 20(1):1-17. PubMed ID: 22110357
[TBL] [Abstract][Full Text] [Related]
16. Double Attack to Oxidative Stress in Neurodegenerative Disorders: MAO-B and Nrf2 as Elected Targets.
Basagni F; Di Paolo ML; Cozza G; Dalla Via L; Fagiani F; Lanni C; Rosini M; Minarini A
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959843
[TBL] [Abstract][Full Text] [Related]
17. Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration.
Ramsay RR; Majekova M; Medina M; Valoti M
Front Neurosci; 2016; 10():375. PubMed ID: 27597816
[TBL] [Abstract][Full Text] [Related]
18. Correlation intensity index-index of ideality of correlation: A hyphenated target function for furtherance of MAO-B inhibitory activity assessment.
Bhawna ; Kumar S; Kumar P; Kumar A
Comput Biol Chem; 2024 Feb; 108():107975. PubMed ID: 37950961
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting Monoamine Oxidase in CNS and CVS would be a Promising Approach to Mitigating Cardiovascular Complications in Neurodegenerative Disorders.
Srivastava P; Sudevan ST; Thennavan A; Mathew B; Kanthlal SK
CNS Neurol Disord Drug Targets; 2024; 23(3):331-341. PubMed ID: 36872357
[TBL] [Abstract][Full Text] [Related]
20. A need for clinical trial: re-purposing the Monoamine Oxidase Inhibitors (MAO-I) for rheumatoid arthritis (RA).
Bala A
Inflammopharmacology; 2023 Dec; 31(6):3367-3370. PubMed ID: 37558921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
